What is MyHep LVIR?
MyHep LVIR™ is an antiviral medication formulated by Mylan Pharmaceuticals, a global company that specializes in the manufacture of generic medical products. Each tablet is composed of 90mg of ledipasvir, a viral nonstructural protein 5A (NS5A) inhibitor, and 400mg of sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase. This drug is prescribed for the treatment of chronic hepatitis C, as it reduces the viral load and transmission within the body. Each bottle of MyHep LVIR™ contains 28 tablets that must be stored at a temperature between 15℃ and 30℃.
1 tablet of MyHep LVIR™ should be taken once daily after eating. The duration of treatment ranges from 8 to 24 weeks; the appropriate duration depends on the genotypes of hepatitis C virus. It is recommended to take the medication at the same time every day, preferably in the morning to prevent possible sleeping disorders. For the best treatment outcomes, patients should avoid missing any doses.
MyHep LVIR™ is contraindicated in patients who are allergic to ledipasvir and sofosbuvir, as well as the other excipients in the drug. Additionally, this medication is also contraindicated in patients taking rosuvastatin.
Commonly reported side effects associated with MyHep LVIR™ are:
Consult your health-care provider if you experience any of the following:
- Decreased appetite;
- Difficult breathing;
Carefully read to the product instruction manual for a detailed list of possible side effects.
You should not use MyHep LVIR™ with other formulations that contain sofosbuvir. To prevent the exacerbation of other medical conditions, caution must be exerted in certain cases.
- Use with caution if you have decompensated cirrhosis or are awaiting liver transplant or are post-liver transplant, as the efficacy of using this drug under these circumstances has not yet been examined;
- Use with caution if you have severe bradycardia and heart block. Some patients have experienced a severely slow heart rate and heart blocks when the drug formulation is used in combination with amiodarone, or other drugs that lower the heart rate.
Patients with serious medical conditions must be carefully monitored to avoid complications.
MyHep LVIR™ contains 2 different active ingredients that individually interact with certain drugs, including rifampicin, phenytoin, and carbamazepine. Interactions with alcohol is unknown. Carefully refer to the product instruction manual for a detailed list of possible drug interactions. Inform your doctor of all medications and supplements you are taking in order to reduce the risks of harmful drug interactions.
Pregnancy & Lactation
This medication is not recommended for use in pregnant or breastfeeding patients. Your doctor will discuss the risks and benefits of using this drug in necessary cases.
Currently, the highest documented doses of ledipasvir and sofosbuvir were 120mg taken twice daily for 10 days and a single dose of 1200mg, respectively. The healthy research subjects did not experience any unpleasant effects; however, the consequences of higher doses remain unknown. Patients who have accidentally overdosed on MyHep LVIR™ must be monitored carefully for any evidence of toxicity. Standard supportive measures, such as monitoring the vital signs and clinical symptoms, are necessary for adequate recovery. If you suspect an overdose, call your local poison control center.
Alternative Brand Names
An alternative brand name is Harvoni®, which contains equal doses ledipasvir and sofosbuvir.
Reviews are only written by verified customers who have purchased this product.